The EPS projection of Flex Pharma, Inc. (NASDAQ:FLKS) for quarter ended 2016-09-30 is $-0.74. A week before, the EPS forecast was $-0.74 against target of $-0.74, a month earlier. This estimate stood at $-0.74 60 days earlier versus forecast of $-0.74 90 days earlier, confirming a deviation of 0%.
Flex Pharma, Inc. (NASDAQ:FLKS) reported that 18 days ago, the positive EPS revisions were 1 and negative revisions at 1.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 1, 1, 0 and 1, respectively.
The downgrade of EPS estimates for Flex Pharma, Inc. (NASDAQ:FLKS) in the preceding 120, 60, 30 and 90 days were 1, 1, 0 and 1, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Flex Pharma, Inc. (NASDAQ:FLKS) was $-0.74. This projection was computed after accounting 3 calls. As reported on 2016-05-04 the EPS was $-0.61. The change was $-0.02, demonstrating a percentage deviation of -3.39%. The projections confirmed a standard deviation of 0.25.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Flex Pharma, Inc. (NASDAQ:FLKS) stands at $0.263 and the median estimate at $0.21. Almost 3 analysts announced their estimates.
The highest estimate is $0.5 while the lowest target is $0.079 showing standard deviation of 0.215%.
As many as 3 analysts released sales estimates reised in upside while 3 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 3 revised sales number projection on upside while 3 lowered the sales target, demonstrating a deviation of -25.915%.
A quarter ago, 3 hiked sales estimations and 3 reduced sales forecast. Flex Pharma, Inc. (NASDAQ:FLKS) stated that the change in forecast was -65.844%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...